Search
CG Oncology Inc
CGONAdd to Watchlist
74.645USD
-3.095-3.98%
Market hours 09/23, 11:08（ET）
6.58BMarket Cap
LossP/E TTM
CG Oncology Inc (CGON) Stock Price Target & Forecast
Analyst Rating
Based on 15 analysts giving stock ratings to CG Oncology Inc in the past month.
Buy
3 Strong Buy
11 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
90.667USD+21.50%
CGON Analyst Recommendation Trends
In the current month, CGON has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the last month is 90.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
2
11
12
12
12
12
12
12
12
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
16
15
15
15
15
15
14
CGON Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, CGON EPS is projected to reach -0.841 in FY2026Q3, following reported EPS of -0.896 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.61
-0.57
-0.66
-0.84
-0.85
Actual
-0.52
-0.71
-0.90
--
--
Surprise
+16.03%
-25.88%
-34.93%
--
--
FAQs
What is CG Oncology Inc's expected revenue for the next quarter?
CG Oncology Inc's expected revenue is 534.17K.
What is CG Oncology Inc's price target?
Analysts forecast that CG Oncology Inc's price target is USD 90.67, with the highest forecast at USD 108.00 and the lowest forecast at USD 79.00.
How have CG Oncology IncCGON's recent earnings per share performed?
The market expectation was USD -0.90, while CG Oncology IncCGON's earnings per share (EPS) for the previous quarter was USD -0.71. EPS for the next quarter is expected at USD -0.84.
What is the analyst rating for CG Oncology Inc?
Based on the ratings of CG Oncology Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.